These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2719900)

  • 1. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of propafenone metaboliser phenotype from plasma and urine excretion data.
    Latini R; Belloni M; Bernasconi R; Cappiello E; Giani P; Landolina M; Leopaldi D; Castel JM
    Eur J Clin Pharmacol; 1992; 42(1):111-4. PubMed ID: 1541308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE; Roden DM
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.
    Turgeon J; Pavlou HN; Wong W; Funck-Brentano C; Roden DM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):642-9. PubMed ID: 2123007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state plasma concentrations of propafenone--chirality and metabolism.
    Volz M; Mitrovic V; Schlepper M
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):370-5. PubMed ID: 7952800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy.
    Steurer G; Weber H; Schmidinger H; Plass H; Frey B; Pürerfellner H; Probst P
    Eur Heart J; 1991 Apr; 12(4):526-32. PubMed ID: 2065687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.
    Klein RC; Huang SK; Marcus FI; Horwitz L; Fenster PE; Rushforth N; Kirsten EB
    Am Heart J; 1987 Sep; 114(3):551-8. PubMed ID: 3630896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers.
    Thompson KA; Iansmith DH; Siddoway LA; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1988 Mar; 244(3):950-5. PubMed ID: 3252042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.
    Lee JT; Kroemer HK; Silberstein DJ; Funck-Brentano C; Lineberry MD; Wood AJ; Roden DM; Woosley RL
    N Engl J Med; 1990 Jun; 322(25):1764-8. PubMed ID: 1971708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE; Philippon F; Gilbert M; Champagne J; Michaud V; Charbonneau L; Pruneau G; Hamelin BA; Geelen P; Turgeon J
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.